163 related articles for article (PubMed ID: 27067410)
1. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
2. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
3. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
[TBL] [Abstract][Full Text] [Related]
6. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
7. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Methylation of T-cadherin Can Be a Diagnostic Biomarker for Colorectal Cancer.
Duan BS; Xie LF; Wang Y
Cancer Genomics Proteomics; 2017; 14(4):277-284. PubMed ID: 28647701
[TBL] [Abstract][Full Text] [Related]
9. [Effects of CDH1 gene promoter methylation on expression of E-cadherin and beta-catenin and its clinicopathological significance in colon carcinoma].
Li C; Dong J; Chen MQ; Li WL; Ren JY; Chen SX; Li QT; Geng JW; Miao YD; Yang J
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jul; 14(7):538-41. PubMed ID: 21792768
[TBL] [Abstract][Full Text] [Related]
10. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
11. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.
Wang H; Cui M; Zhang S; He J; Song L; Chen Y
Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987
[TBL] [Abstract][Full Text] [Related]
12. [Meta-analysis of association between E-cadherin promoter methylation and lung cancer risk].
Zeng Y; Liu R; Zhang H
Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):353-8. PubMed ID: 23866665
[TBL] [Abstract][Full Text] [Related]
13. CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis.
Liu G
Future Oncol; 2018 Jan; 14(1):51-63. PubMed ID: 29237293
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
Ling ZQ; Li P; Ge MH; Zhao X; Hu FJ; Fang XH; Dong ZM; Mao WM
Int J Mol Med; 2011 May; 27(5):625-35. PubMed ID: 21373750
[TBL] [Abstract][Full Text] [Related]
15. Association between
Fan Z; Chen R; Li M; Gu J; Li X; Wei W
Expert Rev Mol Diagn; 2022 Sep; 22(9):895-903. PubMed ID: 36254608
[TBL] [Abstract][Full Text] [Related]
16. Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
Xiao X; Cai F; Niu X; Shi H; Zhong Y
PLoS One; 2016; 11(9):e0163257. PubMed ID: 27648827
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.
Chang Z; Zhou H; Liu Y
Tumour Biol; 2014 Oct; 35(10):10503-13. PubMed ID: 25056535
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
